CORPORATE PRESENTATION
A leading gene therapy biotechnology company
Disclaimer
This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.
Corporate Overview
Clinical-stage gene therapy company
• Focused on severe retinal degenerative pathologies leading to blindness as well as CNS diseases
• Well positioned to advance disruptive gene therapy technologies in ophthalmology to commercialization
Two disruptive technology platforms
• Mitochondrial targeting sequence (MTS)
• Optogenetics
Lead projects target:
• GS010 - Leber Hereditary Optic Neuropathy (Phase III)
• GS030 - Retinitis pigmentosa and dry-AMD (Phase I/II)
Listed on Euronext Paris (SIGHT)
• Established in 2012, IPO in July 2016 (EUR45m)
• GenSight Biologics Inc incorporated in the US in May 2017
Page 3
Executive Team
Bernard Gilly Chief Executive OfficerThomas Gidoin Chief Financial OfficerBarrett Katz Chief Medical Officer
PIXIUM VISION (Since 2011) Chairman of the Board, Founder
FOVEA PHARMA (2005-2009) Chairman & CEO - sold to Sanofi
SOFINNOVA PARTNERS (2000-2005) Managing Partner
TRANSGENE (1992-2000) Chairman & CEO
Ph.D. in biology and bio-economicsDBV TECHNOLOGIES (2012-2015) VP of Finance
IPSEN (2008-2011)
UK Operations Controller (London) Senior Financial Analyst (Paris)
ERNST & YOUNG (2007-2008) Auditor
MONTEFIORE MED CENTER & A. EINSTEIN COLLEGE OF MEDICINE, NY, USA (2011-2017) Prof. of Ophthalmology, Neurology and Neurosurgery
DANUBE PHARMA (2009-2011) CEO
FOVEA PHARMA (2007-2009) CMO
EYETECH (2005-2007)
VP of Medical Affairs and Strategy
MD, Board-certified ophthalmologist & neurologist
Degenerative retinal diseases
GenSight targets 3 areas of unmet needs: LHON, RP & DRY AMD
PHOTORECEPTOR CELLS TRANSFORM LIGHT
INTO ELECTRIC SIGNALS IN THE EYE
ELECTRIC SIGNALS ARE SENT TO THE VISUAL CORTEX OF THE BRAIN VIA THE GANGLION CELLS FORMINGTHE OPTIC NERVE
Degeneration of RGCs
Degeneration of PRs
RETINITIS PIGMENTOSA (RP) GEOGRAPHIC ATROPHY (Late stage form ofAge-Related Macular Degeneration - AMD)
Source: Company
Attachments
- Original document
- Permalink
Disclaimer
Gensight Biologics SA published this content on 31 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 31 October 2018 13:52:01 UTC